GenSight Biologics Publishes Study Comparing LHON Treatments

Event summary

  • GenSight Biologics published a Matching Adjusted Indirect Comparison (MAIC) study in the April 2026 issue of the British Journal of Ophthalmology.
  • The study compared outcomes of GS010/LUMEVOQ®, GenSight’s gene therapy for ND4-LHON, with idebenone, the only approved treatment for LHON.
  • GS010/LUMEVOQ® has not yet received marketing authorization in any country.
  • GenSight’s pipeline includes GS030, an optogenetic treatment for late-stage Retinitis Pigmentosa, currently in Phase I/II trials.

The big picture

GenSight Biologics is positioning itself as a leader in gene therapy for rare retinal diseases, with LHON as a key focus. The MAIC study reinforces its competitive edge over existing treatments, but regulatory approval remains a critical hurdle. The company’s pipeline diversification into optogenetics for Retinitis Pigmentosa further strengthens its long-term strategy in addressing unmet needs in retinal neurodegeneration.

What we're watching

Regulatory Progress
Whether GS010/LUMEVOQ® can secure marketing authorization, given the positive comparative data.
Clinical Execution
The pace at which GenSight advances GS030 through Phase I/II trials for Retinitis Pigmentosa.
Competitive Positioning
How the MAIC study impacts GenSight’s strategic advantage over idebenone in the LHON treatment landscape.

Related topics

Clinical Trials